• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    US Stocks Mostly Flat; Jobless Claims Decline In Latest Week

    11/9/23 9:43:47 AM ET
    $ASTR
    $ATRA
    $EVA
    $GVH
    Transportation Services
    Consumer Discretionary
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ASTR alert in real time by email

    U.S. stocks traded mostly flat this morning, following the release of jobless claims data.

    Following the market opening Thursday, the Dow traded down 0.02% to 34,105.13 while the NASDAQ rose 0.01% to 13,651.18. The S&P 500 also fell, dropping, 0.01% to 4,382.36.

    Check This Out: Costco, Robinhood And 2 Other Stocks Insiders Are Selling

     

    Leading and Lagging Sectors

     

    Energy shares rose by 0.8% on Thursday.

    In trading on Thursday, health care shares fell by 1%.

     

    Top Headline

     

    U.S. initial jobless claims fell by 3,000 to 217,000 in the week ending Nov. 9, compared to market estimates of 218,000.

     

    Equities Trading UP

     

    Astra Space, Inc. (NASDAQ:ASTR) shares shot up 74% to $1.29 after the company announced it received a non-binding proposal from founders Chris Kemp and Adam London offering to acquire all of the outstanding common stock of the company not currently owned by Kemp and London.

    Shares of Intelligent Bio Solutions Inc. (NASDAQ:INBS) got a boost, shooting 52% to $0.3447 as the company posted first-quarter results.

    Globavend Holdings Limited (NASDAQ:GVH) shares were also up, gaining 40% to $3.61. Globavend Holdings recently announced pricing of $6 million initial public offering of 1.5 million shares of common stock at a price of $4 per share.

     

    Equities Trading DOWN

     

    Tempo Automation Holdings, Inc (NASDAQ:TMPO) shares dropped 74% to $0.0020.

    Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) were down 67% to $0.4044 after the company said that primary analysis data from its Phase 2 EMBOLD study of ATA188 in non-active progressive multiple sclerosis (PMS) did not meet the primary endpoint of confirmed disability improvement (CDI) by expanded disability status scale (EDSS) at 12 months compared to placebo.

    Enviva Inc. (NYSE:EVA) was down, falling 67% to $1.28 following third-quarter results. Enviva named Glenn Nunziata as interim Chief Executive Officer in addition to his CFO role.

    Also Check This Out: Jim Cramer Cautions Against Investing In World's Top Scotch Whisky Distiller: 'Getting Bad Vibes'

     

    Commodities

     

    In commodity news, oil traded up 0.5% to $75.73 while gold traded down 0.3% at $1,952.40.

    Silver traded down 0.7% to $22.565 on Thursday while copper fell 0.4% to $3.6250.

     

    Euro zone

     

    European shares were higher today. The eurozone’s STOXX 600 climbed 0.5%, London’s FTSE 100 rose 0.2% while Spain’s IBEX 35 Index rose 0.8% The German DAX rose 0.4% French CAC 40 rose 0.6%, while Italy’s FTSE MIB Index rose 0.5%.

     

    Asia Pacific Markets

     

    Asian markets closed mixed on Thursday, with Japan’s Nikkei 225 gaining 1.49%, Hong Kong’s Hang Seng Index falling 0.33% and China’s Shanghai Composite Index rising 0.03%. India’s S&P BSE Sensex, meanwhile, fell around 0.22%.

    China's consumer prices fell by 0.2% year-over-year in October, while producer prices fell 2.6% year-over-year in October. The gauge for Japan's service sector sentiment fell to 49.5 in October versus 49.9 a month ago. Japan's current account surplus increased to JPY 2,726.3 billion in September, while value of loans in Japan climbed 2.8% year-over-year in October.

     

    Economics

     

    U.S. initial jobless claims fell by 3,000 to 217,000 in the week ending Nov. 9, compared to market estimates of 218,000.

    Now Read This: How To Earn $500 A Month From Ralph Lauren Stock Following Upbeat Earnings

    Get the next $ASTR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ASTR
    $ATRA
    $EVA
    $GVH

    CompanyDatePrice TargetRatingAnalyst
    Atara Biotherapeutics Inc.
    $ATRA
    1/13/2026$6.00Buy → Hold
    Canaccord Genuity
    Enviva Inc.
    $EVA
    11/16/2023Strong Buy → Mkt Perform
    Raymond James
    Atara Biotherapeutics Inc.
    $ATRA
    11/9/2023Outperform → In-line
    Evercore ISI
    Atara Biotherapeutics Inc.
    $ATRA
    11/9/2023Buy → Neutral
    H.C. Wainwright
    Atara Biotherapeutics Inc.
    $ATRA
    11/9/2023$31.00 → $1.00Buy → Neutral
    Mizuho
    Enviva Inc.
    $EVA
    10/18/2023$14.00 → $10.00Neutral
    JP Morgan
    Enviva Inc.
    $EVA
    10/6/2023$8.00Neutral
    Goldman
    Enviva Inc.
    $EVA
    5/4/2023$40.00 → $10.00Buy → Sell
    Truist
    More analyst ratings

    $ASTR
    $ATRA
    $EVA
    $GVH
    SEC Filings

    View All

    Intelligent Bio Solutions Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)

    2/5/26 8:53:26 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    Intelligent Bio Solutions Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)

    1/28/26 5:15:25 PM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    SEC Form NT 20-F filed by Globavend Holdings Limited

    NT 20-F - Globavend Holdings Ltd (0001978527) (Filer)

    1/28/26 4:01:26 PM ET
    $GVH
    Integrated Freight & Logistics
    Industrials

    $ASTR
    $ATRA
    $EVA
    $GVH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Atara Biotherapeutics downgraded by Canaccord Genuity with a new price target

    Canaccord Genuity downgraded Atara Biotherapeutics from Buy to Hold and set a new price target of $6.00

    1/13/26 10:16:38 AM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Enviva downgraded by Raymond James

    Raymond James downgraded Enviva from Strong Buy to Mkt Perform

    11/16/23 7:17:22 AM ET
    $EVA
    Forest Products
    Basic Materials

    Atara Biotherapeutics downgraded by Evercore ISI

    Evercore ISI downgraded Atara Biotherapeutics from Outperform to In-line

    11/9/23 9:00:28 AM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ASTR
    $ATRA
    $EVA
    $GVH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Intelligent Bio Solutions Expects to Report Fiscal Second Quarter 2026 Revenue Growth of Approximately 48% Year-Over-Year, Surpassing $2 Million in Total Revenue for First Half of Fiscal Year

    Expected record fiscal second quarter revenue increase driven by expanding customer base and strong growth across all product categories Reader sales expected to post year-over-year growth of more than 100% in fiscal Q2, expanding installed base to drive sustained recurring cartridge revenue NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced preliminary, unaudited revenue results for the fiscal second quarter and first half 2026 ended December 31, 2025. The Company expects to report strong revenue growth across all pr

    2/5/26 8:30:00 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    Intelligent Bio Solutions Initiates Additional Clinical Studies for FDA 510(k) Submission Supporting Planned Entry into Multi-Billion Dollar U.S. Market

    Clinical studies designed to support FDA clearance and planned commercial launch into the world's largest drug screening market  Company anticipates full data analysis by the end of March 2026; data to be incorporated into FDA 510(k) submission package NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the commencement of its clinical study program to support its new FDA 510(k) submission for U.S. market clearance of its Intelligent Fingerprinting Drug Screening System for detection of the opiate codeine. As part of

    1/28/26 8:30:00 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    PIERRE FABRE PHARMACEUTICALS STATEMENT REGARDING RECEIPT OF COMPLETE RESPONSE LETTER FOR TABELECLEUCEL BIOLOGICS LICENSE APPLICATION FROM THE U.S. FOOD AND DRUG ADMINISTRATION

    SECAUCUS, N.J., Jan. 12, 2026 /PRNewswire/ -- On January 9, 2026, Pierre Fabre Pharmaceuticals, Inc. received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) stating that the Agency is unable to approve the tabelecleucel Biologics License Application (BLA) in its present form. We are surprised and deeply disappointed by the FDA's decision, particularly given the urgent and life-threatening unmet medical need faced by patients with Epstein-Barr virus–positive post-transplant lymphoproliferative disease (EBV+ PTLD) after failure of standard-of-c

    1/12/26 8:05:00 AM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ASTR
    $ATRA
    $EVA
    $GVH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Panacea Innovation Ltd bought $670,422 worth of shares (55,000 units at $12.19) (SEC Form 4)

    4 - Atara Biotherapeutics, Inc. (0001604464) (Issuer)

    8/19/25 8:15:04 PM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Panacea Innovation Ltd bought $186,372 worth of shares (19,335 units at $9.64) (SEC Form 4)

    4 - Atara Biotherapeutics, Inc. (0001604464) (Issuer)

    7/21/25 9:00:05 AM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Stanford Scott bought $22,315 worth of shares (18,442 units at $1.21) (SEC Form 4)

    4 - Astra Space, Inc. (0001814329) (Issuer)

    12/28/23 4:11:34 PM ET
    $ASTR
    Transportation Services
    Consumer Discretionary

    $ASTR
    $ATRA
    $EVA
    $GVH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Panacea Innovation Ltd sold $489,019 worth of shares (80,554 units at $6.07) (SEC Form 4)

    4 - Atara Biotherapeutics, Inc. (0001604464) (Issuer)

    1/14/26 9:16:25 PM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Panacea Innovation Ltd exercised 48,737 shares at a strike of $0.00 and covered exercise/tax liability with 1 shares (SEC Form 4)

    4 - Atara Biotherapeutics, Inc. (0001604464) (Issuer)

    12/1/25 5:00:04 PM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and CEO Nguyen Anhco sold $38,437 worth of shares (2,915 units at $13.19), decreasing direct ownership by 4% to 64,974 units (SEC Form 4)

    4 - Atara Biotherapeutics, Inc. (0001604464) (Issuer)

    11/19/25 4:55:17 PM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ASTR
    $ATRA
    $EVA
    $GVH
    Leadership Updates

    Live Leadership Updates

    View All

    Merlin Appoints Ryan Carrithers as Chief Financial Officer, Increasing Public Market Readiness

    Carrithers brings to Merlin a unique blend of technical expertise, capital markets experience, and operational rigor, backed by a proven record in scaling innovative automation and aerospace companies Merlin Labs, Inc., a leading developer of assured, autonomous flight technology for defense customers, today appointed Ryan Carrithers as its new Chief Financial Officer. Carrithers joins Merlin at a pivotal moment as the company prepares to go public in a Business Combination with Inflection Point Acquisition Corp. IV (NASDAQ:BACQ). In this role, he will oversee all of Merlin's financial operations and strategy, investor relations, M&A or strategic partnerships that support its autonomy road

    11/4/25 9:00:00 AM ET
    $ASTR
    $BACQ
    $DNA
    Transportation Services
    Consumer Discretionary
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CDR-Life Appoints Pascal Touchon to the Board of Directors to Support Continued Growth and Advancement of Next Generation T Cell Engager Platform

    Experienced, strategic biopharma leader with 40 years of global biopharma experience CDR-Life today announced the appointment of Pascal Touchon, DVM, MBA, to its Board of Directors. Dr. Touchon brings 40 years of international experience in the biopharmaceutical industry, with extensive expertise in oncology and strategic leadership that will further strengthen CDR-Life as it advances its innovative M-gager® platform and pipeline of T cell engager (TCE) therapeutics. "We are delighted to welcome Pascal to our Board of Directors," said Dominik Escher, Ph.D., Chairman of CDR-Life's Board of Directors. "Pascal's remarkable track record in developing and commercializing transformative thera

    5/28/25 8:00:00 AM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors

    Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, announced the appointment of James Huang and Nachi Subramanian to its Board of Directors, effective following the completion the Company's previously announced $16 million offering that was announced on May 15, 2025. The offering closed on May 16, 2025. Mr. Huang has over 37 years of biotech experience and is the Founder and Managing Partner of Panacea Venture. Prior to Panacea Venture, Mr. Huang was a Managing Partner at Kleiner Perkins (KPCB) China where h

    5/16/25 8:50:00 PM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ASTR
    $ATRA
    $EVA
    $GVH
    Financials

    Live finance-specific insights

    View All

    Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel)

    U.S. Food and Drug Administration has issued a Complete Response Letter (CRL) Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the EBVALLO™ (tabelecleucel) Biologics License Application (BLA) as monotherapy treatment for adult and pediatric patients two years of age and older with Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD), who have received at least one

    1/12/26 8:00:00 AM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Intelligent Bio Solutions Reports Fiscal 2026 First Quarter Financial Results and Operational Highlights, Delivering Record Revenue Growth

    Record quarterly revenue of $1.11 million, an increase of 32% sequentially and 28% year-over-year, driven by consumable cartridge sales and customer base expansion Gross profit margins increased 690 basis points year-over-year to 46.6%, reflecting improved operational efficiency and greater revenue percentage from higher margin cartridge sales NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results and operational highlights for the fiscal first quarter ended September 30, 2025. The fiscal 2026 first

    11/12/25 8:30:00 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    Intelligent Bio Solutions Reports Fiscal 2025 Fourth Quarter and Full Year Results, Highlighting Progress on Planned U.S. Market Expansion, Revenue Growth and Increased Operational Efficiencies

    Company advanced efforts to secure U.S. FDA 510(k) clearance to advance on path towards planned U.S. market expansion beyond Forensic Use Only settings Fourth quarter sequential and year-on-year revenue growth of 16%, supported by increased demand for drug testing cartridges NEW YORK, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results and operational highlights for the fiscal fourth quarter and full-year ended June 30, 2025. Fiscal 2025 marked a year of growth for the Company, driven by higher-margin cart

    8/15/25 8:30:00 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    $ASTR
    $ATRA
    $EVA
    $GVH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Globavend Holdings Limited

    SC 13G - Globavend Holdings Ltd (0001978527) (Subject)

    11/20/24 4:36:45 PM ET
    $GVH
    Integrated Freight & Logistics
    Industrials

    Amendment: SEC Form SC 13G/A filed by Intelligent Bio Solutions Inc.

    SC 13G/A - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Subject)

    11/14/24 7:16:17 PM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Atara Biotherapeutics Inc.

    SC 13G/A - Atara Biotherapeutics, Inc. (0001604464) (Subject)

    11/14/24 6:10:20 PM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care